Portfolio

  • Home
  • Portfolio
  • Companies
Portfolio

PORTFOLIO COMPANY SUMMARY

The RD Fund focuses on companies with late preclinical to clinical stage programs. Preclinical projects are generally within 18 to 24 months of clinical testing. The RD Fund has invested globally in multiple companies, including internally conceived startups working on a range of promising technologies and therapeutic targets, including gene therapy, RNA therapies, neuroprotection and optogenetics.

Eric with child

THERAPEUTIC PIPELINE

  • ProQR
  • Stargazer
  • Atsena
  • Nacuity
  • SparingVision
  • Opus Genetics
  • Vedere Bio II
  • SalioGen
  • Nayan
Therapeutic Pipeline Therapeutic Pipeline

As of June 2022